PURPOSE: To evaluate clinical and tumor characteristics in patients receiving high-dose chemotherapy and autologous peripheral stem-cell transplantation (PSCT) or bone marrow transplantation (ABMT) for relapsed or primary refractory non-Hodgkin's lymphoma (NHL). PATIENTS AND METHODS: One hundred fifty-eight patients with NHL received high-dose chemotherapy and ABMT or PSCT. A multivariate analysis of characteristics was performed for comparison of the long-term failure-free survival (FFS) rate. RESULTS: Using a multivariate analysis, a prognostic model was constructed with patients in the good-prognosis group being those without a mass > or = 10 cm at the time of transplant, and no more than one of the following characteristics: three or more prior chemotherapy regimens, lactate dehydrogenase (LDH) level above normal, and chemotherapy resistance. Patients in the poor-prognosis group had a mass > or = 10 cm, or two of the other characteristics noted. The poor-prognosis group had a 3-year FFS rate of 10%, compared with a 45% 3-year FFS in the good-prognosis group (P < .001). Within the prognostic groups, there was no difference in the 3-year FFS rate of the poor-prognosis patients who received ABMT versus PSCT (10% v 12%; not significant). However, in the good-prognosis group, patients who received ABMT had a 3-year FFS rate of 32%, compared with 70% for those who received PSCT (P < .008). CONCLUSION: This prognostic model can identify patients with good and poor prognoses following high-dose chemotherapy and ABMT or PSCT for aggressive NHL. In good-prognosis patients, those who received PSCT had a superior FFS rate.
PURPOSE: To evaluate clinical and tumor characteristics in patients receiving high-dose chemotherapy and autologous peripheral stem-cell transplantation (PSCT) or bone marrow transplantation (ABMT) for relapsed or primary refractory non-Hodgkin's lymphoma (NHL). PATIENTS AND METHODS: One hundred fifty-eight patients with NHL received high-dose chemotherapy and ABMT or PSCT. A multivariate analysis of characteristics was performed for comparison of the long-term failure-free survival (FFS) rate. RESULTS: Using a multivariate analysis, a prognostic model was constructed with patients in the good-prognosis group being those without a mass > or = 10 cm at the time of transplant, and no more than one of the following characteristics: three or more prior chemotherapy regimens, lactate dehydrogenase (LDH) level above normal, and chemotherapy resistance. Patients in the poor-prognosis group had a mass > or = 10 cm, or two of the other characteristics noted. The poor-prognosis group had a 3-year FFS rate of 10%, compared with a 45% 3-year FFS in the good-prognosis group (P < .001). Within the prognostic groups, there was no difference in the 3-year FFS rate of the poor-prognosis patients who received ABMT versus PSCT (10% v 12%; not significant). However, in the good-prognosis group, patients who received ABMT had a 3-year FFS rate of 32%, compared with 70% for those who received PSCT (P < .008). CONCLUSION: This prognostic model can identify patients with good and poor prognoses following high-dose chemotherapy and ABMT or PSCT for aggressive NHL. In good-prognosis patients, those who received PSCT had a superior FFS rate.
Authors: Auayporn Nademanee; Stephen Forman; Arturo Molina; Henry Fung; David Smith; Andy Dagis; Cheuk Kwok; Dave Yamauchi; Anne-Line Anderson; Peter Falk; Amrita Krishnan; Mark Kirschbaum; Neil Kogut; Ryotaro Nakamura; Margaret O'donnell; Pablo Parker; Leslie Popplewell; Vinod Pullarkat; Roberto Rodriguez; Firoozeh Sahebi; Eileen Smith; David Snyder; Anthony Stein; Ricardo Spielberger; Jasmine Zain; Christine White; Andrew Raubitschek Journal: Blood Date: 2005-07-07 Impact factor: 22.113
Authors: Ho-Young Yhim; Yael Eshet; Ur Metser; Chae-Hong Lim; Katherine Lajkosz; Keren Isaev; Matthew Cooper; Anca Prica; Vishal Kukreti; Sita Bhella; Noémie Lang; Kyung-Han Lee; Wei Xu; David Hodgson; Richard Tsang; Sang Eun Yoon; Seok Jin Kim; Won Seog Kim; Michael Crump; John Kuruvilla; Robert Kridel Journal: Blood Adv Date: 2020-11-24
Authors: Santosha A Vardhana; Craig S Sauter; Matthew J Matasar; Andrew D Zelenetz; Natasha Galasso; Kaitlin M Woo; Zhigang Zhang; Craig H Moskowitz Journal: Br J Haematol Date: 2016-12-16 Impact factor: 6.998
Authors: Ulrich J M Mey; Vandana Jha; John W Strehl; Marcus Gorschlueter; Christian Rabe; Eckfried Hoebert; Henning Popp; Ingo G H Schmidt-Wolf Journal: Ger Med Sci Date: 2007-06-19